Exelixis Inc
NASDAQ:EXEL
Exelixis Inc
Exelixis Inc., founded in 1994, embarked on its journey in the biotech sector with a sharp focus on genomics and drug discovery. This San Francisco-based biopharmaceutical company has firmly imprinted its name within the oncology space, thanks to its innovative research and development endeavors. One of the company's flagship achievements is the development and commercialization of cabozantinib, a compound used to treat various types of cancer. Marketed under the brand names like Cabometyx and Cometriq, cabozantinib targets tumor growth and angiogenesis, the process through which tumors develop their own blood supply. By honing in on these therapeutic areas, Exelixis capitalizes on its robust pipeline and partnerships with other healthcare stakeholders, thus carving out a niche in precision medicine.
The company's business model primarily revolves around the development, commercialization, and strategic licensing of its drug candidates. Through extensive research and collaborative efforts, Exelixis not only advances its own proprietary medications but also licenses out their discoveries to maximize outreach and revenue potential. Revenue streams are generated through product sales, developmental milestones, and royalties, with significant investments poured back into research to fuel future innovation. In the intricate dance of biotech, Exelixis thrives on balancing the risk of high research costs with the lucrative potential of breakthrough cancer treatments, demonstrating a conscious strategy of leveraging scientific expertise into a commercially viable portfolio.
Exelixis Inc., founded in 1994, embarked on its journey in the biotech sector with a sharp focus on genomics and drug discovery. This San Francisco-based biopharmaceutical company has firmly imprinted its name within the oncology space, thanks to its innovative research and development endeavors. One of the company's flagship achievements is the development and commercialization of cabozantinib, a compound used to treat various types of cancer. Marketed under the brand names like Cabometyx and Cometriq, cabozantinib targets tumor growth and angiogenesis, the process through which tumors develop their own blood supply. By honing in on these therapeutic areas, Exelixis capitalizes on its robust pipeline and partnerships with other healthcare stakeholders, thus carving out a niche in precision medicine.
The company's business model primarily revolves around the development, commercialization, and strategic licensing of its drug candidates. Through extensive research and collaborative efforts, Exelixis not only advances its own proprietary medications but also licenses out their discoveries to maximize outreach and revenue potential. Revenue streams are generated through product sales, developmental milestones, and royalties, with significant investments poured back into research to fuel future innovation. In the intricate dance of biotech, Exelixis thrives on balancing the risk of high research costs with the lucrative potential of breakthrough cancer treatments, demonstrating a conscious strategy of leveraging scientific expertise into a commercially viable portfolio.
Strong Revenue Growth: Exelixis reported third quarter 2025 total revenue of $598 million, with cabozantinib franchise product revenue up 14% year-over-year to $543 million, driven by robust US demand and new indication launches.
Guidance Raised: The company narrowed its full-year 2025 revenue and net product revenue guidance to the upper end of prior ranges, now expecting total revenue of $2.3–2.35 billion and net product revenue of $2.1–2.15 billion.
STELLAR-303 Success: Positive Phase III STELLAR-303 data showed a 20% reduction in risk of death for zanzalintinib plus atezolizumab in colorectal cancer, paving the way for a planned NDA filing in December 2025.
Neuroendocrine Tumor Launch: The CABOMETYX launch in neuroendocrine tumors is off to a strong start, capturing over 40% new patient share in the oral therapy segment and targeting over $100 million in revenue for 2025.
Strategic Investments: Exelixis is expanding its GI sales team and building commercial infrastructure to support anticipated growth in both existing and upcoming GI oncology indications.
Capital Allocation & Buybacks: The company remains focused on R&D investment and commercial expansion, while also authorizing an additional $750 million share repurchase program through 2026.
Operating Leverage: R&D expense guidance was lowered by $75 million and SG&A guidance was tightened, reflecting disciplined expense management alongside growth investments.
